Skip to content
value.today
AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

Total raised
$82 M
2 rounds on record
Latest round
$75 M
Mar 2020
First round on record
Aug 2018
Today
Went public
See the company page

AbCellera Biologics Inc. is listed today as AbCellera Biologics Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of AbCellera Biologics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$75 MNo. 2$50 to $250 million

AbCellera Biologics Inc.: Raise no. 2, Mar 2020

Investors in this round

14 investors had bought by the notice of May 27, 2020: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Andrew Booth · Executive Officer
  • Carl Hansen · Executive Officer, Director
  • Stimart Tryn · Executive Officer
  • Veronique Lecault · Director, Executive Officer
  • John Hamer · Director
  • Michael Hayden · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tryn Stimart, General Counsel. Newest notice filed May 27, 2020. Read the notice at the SEC.

equitySEC
Aug 2018$8 MNo. 1$2 to $10 million

AbCellera Biologics Inc.: Raise no. 1, Aug 2018

Investors in this round

1 investor had bought by the notice of Aug 10, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Carl Hansen · Executive Officer, Director
  • Andrew Booth · Director
  • John Hamer · Director
  • Veronique Lecault · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Carl Hansen, President and Chief Executive Officer. Newest notice filed Aug 10, 2018. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company AbCellera Biologics Inc., its revenue in fiscal 2025 came from these product and service lines: Licensing and royalty revenue $46.92 million (62%), Research fees $27.21 million (36%), Milestone payments $1 million (1%).

    Annual report (SEC XBRL) · Dec 2025

  • AbCellera Biologics Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).

    SEC Form D · May 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2020

Products#

  • bamlanivimab

Services#

No services of AbCellera Biologics Inc. are on record.

Investors#

No investor of AbCellera Biologics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding AbCellera Biologics Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AbCellera Biologics Inc.
NameRoleNamed in
Andrew BoothExecutive officerMay 2020
Carl HansenExecutive officerMay 2020
Stimart TrynExecutive officerMay 2020
Veronique LecaultExecutive officerMay 2020
Carl HansenDirectorMay 2020
John HamerDirectorMay 2020
Michael HaydenDirectorMay 2020
Veronique LecaultDirectorMay 2020
Andrew BoothDirectorAug 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.